Alpha-Synuclein Aggregate Discrimination for Parkinson's and MSA Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively discriminate between Parkinson's disease and multiple system atrophy, as both conditions involve α-synuclein aggregation, making it difficult to determine the correct treatment strategy and prognosis.
Innovation Solution
A method involving solutions with α-synuclein monomers that tend to produce rod-like or twisted aggregates, where biological samples are added and allowed to aggregate, with the rate and form of aggregation used to differentiate between Parkinson's disease and multiple system atrophy using thioflavin T fluorescence and electron microscopy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods (ELISA, RT-QUIC, PMCA) are used to detect α-synuclein aggregates, then the amount of aggregates can be quantified, but the ability to discriminate between Parkinson's disease and multiple system atrophy is lost because aggregation curves are equally increased in both diseases
Solution Approach 1:
The invention segments the single aggregate detection into two separate detection systems: one using rod-like aggregate seeds and another using twisted aggregate seeds. This segmentation allows differential detection of disease-specific aggregate conformations, enabling discrimination between PD and MSA while maintaining quantification capability.
Solution Approach 2:
The invention applies local quality by using different seed aggregate conformations (rod-like vs. twisted) in separate reaction systems. Each seed type selectively amplifies corresponding disease-associated aggregate forms, creating localized detection zones with specific diagnostic properties for differentiating PD and MSA.
2Ease of operation
If a single aggregate detection method is used, then the detection process is simple, but the diagnostic discrimination between different diseases is impossible
Solution Approach 1:
The detection system is segmented into two parallel simple assays: one with rod-like seeds and one with twisted seeds. Each assay remains operationally simple, but together they provide discriminatory power through comparative analysis of amplification patterns and aggregate morphologies.
Solution Approach 2:
The invention changes the conformational parameter of the seed aggregates (rod-like vs. twisted) to create differential detection capabilities. By varying this structural parameter while maintaining procedural simplicity, the system achieves both ease of operation and diagnostic precision.
3Quantity of substance
If only the amount of α-synuclein aggregates is measured, then quantification is achieved, but the pathological background specific to each disease is not reflected
Solution Approach 1:
The invention preserves pathological information by detecting not just the quantity but also the conformational quality of aggregates. Different disease states produce distinct aggregate conformations (rod-like vs. twisted) that are selectively amplified by corresponding seeds, maintaining pathological fingerprint information alongside quantification.
Solution Approach 2:
The invention measures both the quantity parameter (aggregate amount) and the conformational parameter (aggregate shape morphology). By simultaneously capturing these two parameters through differential seed amplification, the system reflects the pathological background specific to each disease while maintaining quantification capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables easy and early discrimination between Parkinson's disease and multiple system atrophy, facilitating accurate diagnosis and treatment strategies.
Implementation Method 1
Thioflavin T (may be abbreviated as ThT) is added to the system, which is a compound that emits fluorescence upon binding to α-synuclein fibrillar aggregates.
Implementation Method 2
a small amount of α-synuclein aggregates present in a sample can be amplified by mixing the sample with recombinant α-synuclein monomers purified after expression in Escherichia coli and then subjecting the mixture to stimuli such as shaking and/or ultrasonication
Data Source
AI summary
A method for discriminating between Parkinson's disease and multiple system atrophy, the method comprising the steps of: (1) preparing a solution containing α-synuclein monomers having a tendency to produce rod-like aggregates and/or a solution containing α-synuclein monomers having a tendency to produce twisted aggregates; (2) adding a biological sample from a subject to the solution(s) containing the α-synuclein monomers prepared in step (1); (3) allowing the α-synuclein monomers to aggregate in the solution(s) obtained in step (2); and (4) detecting α-synuclein aggregates formed in step (3).